10 Questions
What is the annualized revenue for Pluvicto® mentioned in the text?
Over USD 700 million
According to Vasant Narasimhan, has the initial estimate of the VISION population underestimated the potential of this population?
Yes
What is the key challenge in meeting the demand for the medicine mentioned in the text?
Expanding capacity to meet the much larger interested population than initially expected
What is the opportunity for Pluvicto® in the PSMAfore study?
To move first into the pre-taxane setting, expanding the patient pool from 27,000 to 42,000 patients.
What are the specific illnesses mentioned in the text that the company is focusing on?
PNH, C3G, aHUS, IC-MPGN
What program does the company have for iptacopan, and in what conditions is it being evaluated?
The company has a program for iptacopan evaluated in geographic atrophy and related retinal diseases.
What is the expected expansion with the PSMAddition study?
Further expansion into the hormonesensitive setting.
How many facilities does the company believe they would need to be able to provide Pluvicto® in the US market to reach the potential basin population across the 3 indications mentioned?
About 500 facilities
What is the company's plan for Pluvicto® in the future?
To evaluate further expansion into the biochemical recurrence setting or the localized prostate cancer setting.
What is the goal of generating a broad set of data for Pluvicto®?
To support its use in as many prostate cancer patients as possible.
This quiz focuses on a BofA Securities research division Q&A session discussing the annualized sales of Pluvicto® and its potential for growth. It touches on supply capacity constraints and the possibility of underestimating the VISION population. Test your understanding of the market expansion and supply challenges for Pluvicto®.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
